Drug intelligence / Profile preview

LNO-L01

Development stage: Preclinical
Lead developer: Linno Pharmaceuticals
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

LNO-L01 is a lipid nanoparticle (LNP)-encapsulated therapeutic candidate developed by Linno Pharmaceuticals (also known as Lingnuo Pharmaceuticals). It is currently in the IND-enabling phase of development for the treatment of genetic diseases. The asset utilizes Linno's proprietary LNP delivery platform, which is designed to deliver nucleic acid payloads (such as mRNA or siRNA) to target tissues to address the underlying causes of rare genetic disorders. As the lead program in Linno's pipeline, LNO-L01 represents the company's primary effort in applying its delivery technology toward rare disease indications.

Beyond the preview

Go deeper on LNO-L01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNO-L01.

Explore the full profile